File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of plasmapheresis on serum levels of clobazam, levetiracetam and topiramate

TitleEffect of plasmapheresis on serum levels of clobazam, levetiracetam and topiramate
Authors
Issue Date2017
PublisherElsevier: Creative Commons. The Journal's web site is located at http://www.journals.elsevier.com/epilepsy-and-behavior-case-reports/
Citation
Epilepsy & Behavior Case Reports, 2017, v. 8, p. 66-68 How to Cite?
AbstractA 27-year-old man with a diagnosis of new onset refractory status epilepticus (NORSE) was treated with five antiseizure drugs (ASDs) including clobazam, levetiracetamand topiramate. He received plasma exchange (PE) for presumed autoimmune etiology. SerumASD levels were seriallymonitored in two sessions. Levels of clobazam, levetiracetam and topiramate were significant reduced by PE. Serum clobazam level dropped down to at least 85% and 75% of the baseline during and after the procedure respectively; levetiracetam dropped down to 83% and 83%; and topiramate dropped to 86% and 79%. The results may imply a theoretical risk of breakthrough seizure during PE due to low ASD levels.
Persistent Identifierhttp://hdl.handle.net/10722/259431
ISSN
2015 SCImago Journal Rankings: 0.246
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTo, HHM-
dc.contributor.authorChang, RSK-
dc.contributor.authorChan, AOK-
dc.contributor.authorChan, WLP-
dc.date.accessioned2018-09-03T04:07:18Z-
dc.date.available2018-09-03T04:07:18Z-
dc.date.issued2017-
dc.identifier.citationEpilepsy & Behavior Case Reports, 2017, v. 8, p. 66-68-
dc.identifier.issn2213-3232-
dc.identifier.urihttp://hdl.handle.net/10722/259431-
dc.description.abstractA 27-year-old man with a diagnosis of new onset refractory status epilepticus (NORSE) was treated with five antiseizure drugs (ASDs) including clobazam, levetiracetamand topiramate. He received plasma exchange (PE) for presumed autoimmune etiology. SerumASD levels were seriallymonitored in two sessions. Levels of clobazam, levetiracetam and topiramate were significant reduced by PE. Serum clobazam level dropped down to at least 85% and 75% of the baseline during and after the procedure respectively; levetiracetam dropped down to 83% and 83%; and topiramate dropped to 86% and 79%. The results may imply a theoretical risk of breakthrough seizure during PE due to low ASD levels.-
dc.languageeng-
dc.publisherElsevier: Creative Commons. The Journal's web site is located at http://www.journals.elsevier.com/epilepsy-and-behavior-case-reports/-
dc.relation.ispartofEpilepsy & Behavior Case Reports-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleEffect of plasmapheresis on serum levels of clobazam, levetiracetam and topiramate-
dc.typeArticle-
dc.identifier.emailChan, WLP: pwlchan@hku.hk-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/j.ebcr.2017.07.002-
dc.identifier.scopuseid_2-s2.0-85029501403-
dc.identifier.hkuros288397-
dc.identifier.volume8-
dc.identifier.spage66-
dc.identifier.epage68-
dc.identifier.isiWOS:000416287600017-
dc.publisher.placeNetherlands-
dc.identifier.issnl2213-3232-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats